Laboratory changes before and after intravenous cyclophosphamide treatment in SLE. Values are median (range)
| Laboratory tests | Before treatment | Initial response 3 (2-7) weeks 3 (2-7) pulses | After the course of treatment 5.3 (0.25-13) months 5 (2-26) pulses | At follow up 56 (5-213) months |
| ESR (mm 1st h) | 44 (10–140) | 27.5 (2–150)3-150 | 26 (2–107)3-150 | 22 (1–130)3-150 |
| Hb (g/dl) | 12.2 ( 5.8–15.7) | 12.2 (8–16) | 12.7 (7.6–15.8) | 12.5 (6.2–15.2) |
| Neutrophils (×109/l) | 5.5 (0.9–31) | 4.7 (1.2–2.6) | 4.6 (1.2–2.8) | 4.3 (1.2–13.5) |
| Lymphocytes (×109/l) | 1.2 (0.12–8) | 1.1 (0.2–5) | 1 (0.1–4.6) | 1 (0.08–4.6) |
| Platelets (×103/l) | 304 (11–1280) | 294 (104–610) | 277 (8–698) | 261 (69–468) |
| CRP (g/dl) | 12 (5–230) | 10 (5–103) | 10 (5–121) | 5 (5–180) |
| Creatinine (μmol/l) | 93 (45–250) | 94 (49–255) | 94 (12–278) | 112 (51–287) |
| 24 h proteinuria (g/d) | 2.5 (0.3–13) | 2.1 (0.2–6)3-150 | 1.8 (0.2–9.3)3-150 | 1.5 (0.1–7)3-150 |
| Albumin (g/l) | 36 (15–51) | 40 (21–48)3-150 | 40 (18–50)3-150 | 40 (25–51)3-150 |
| Anti-dsDNA (IU/ml) | 81 (5–99) | 54 (10–99)3-150 | 49 (5–99)3-150 | 48 (1–16)3-150 |
| C3 (g/l) | 0.88 (0.16–2.4) | 0.9 (0.2–1.8) | 0.9 (0.22–1.98)3-150 | 0.9 (0.32–1.6)3-150 |
| C4 (g/l) | 0.18 (0.03–0.47) | 0.22 (0.06–0.50)3-150 | 0.24 (0.06–0.9)3-150 | 0.23 (0.06–0.9)3-150 |
↵3-150 p < 0.05, Wilcoxon’s signed rank test.